Tekla Life Sciences Investors (HQL) NYSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 447.81M |
| Enterprise Value | 447.74M |
| P/E Ratio | 2.93 |
| PEG Ratio | 0 |
| Price/Sales Ratio | 10.06 |
| Price/Book Ratio | 1.07 |
| Enterprise/Revenue | 10.06 |
| Enterprise/EBITDA | 3.03 |
Fiscal Year
| Fiscal Year | September 30, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 3.32 |
| Operating Margin | 3.32 |
AD
Management Effectiveness
| Return On Assets | 0.35 |
| Return On Equity | 0.37 |
Income Statement
| Revenue | 86.39M |
| Revenue/Share | 1.96 |
| Gross Profit | 86.39M |
| EBITDA | 85.59M |
| Net Income | 85.59M |
| Diluted EPS | 2.96 |
Balance Sheet
| Total Cash | 851,602 |
| Total Cash/Share | 0.03 |
| Total Debt | 0 |
| Total Debt/Equity | 0 |
| Current Ratio | 2.58 |
| Book Value Per Share | 18.44 |
Price History
| 52-Week Change | 38.4 |
| 52-Week High | 22.67 |
| 52-Week Low | 13.88 |
| Moving Average 50 Days | 20.48 |
| Moving Average 200 Days | 18 |
Statistics
| Average Volume | 151,416 |
| Shares Outstanding | 30.41M |
| % Held by Institutions | 25.91 |
Dividend And Splits
| Trailing Annual Dividend Rate | 2.24 |
| Trailing Annual Dividend Yield | 11.34 |
| Payout Ratio | 0.25 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
